Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21607436 | 0.98 | TDP1 (0.42) | TDP1HCRTR2EPHX1MEN1KMT2A | |
| SCHEMBL12598988 | 0.97 | TDP1 (0.44) | TDP1HCRTR2EPHX1MEN1KMT2A | |
| SCHEMBL510027 | 0.93 | TDP1 (0.46) | TDP1HCRTR2EPHX1MEN1KMT2A | |
| SCHEMBL30158378 | 0.86 | TDP1 (0.41) | TDP1HCRTR2EPHX1MEN1KMT2A | |
| SCHEMBL12598205 | 0.86 | HCRTR2 (0.44) | TDP1HCRTR2EPHX1MEN1KMT2A | |
| SCHEMBL4780567 | 0.85 | EPHX1 (0.42) | TDP1HCRTR2EPHX1MEN1KMT2A | |
| SCHEMBL31050668 | 0.84 | HCRTR2 (0.39) | TDP1HCRTR2EPHX1MEN1KMT2A | |
| SCHEMBL1076767 | 0.83 | ALDH1A1 (0.45) | TDP1HCRTR2EPHX1MEN1KMT2A | |
| SCHEMBL1979180 | 0.82 | MEN1 (0.39) | TDP1HCRTR2MEN1KMT2AGAA | |
| SCHEMBL1978460 | 0.82 | USP2 (0.42) | TDP1HCRTR2EPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2025-06-03 | — | — | US | disclosed |
| EP-3792260-B1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | NIPPON SHINYAKU CO LTD (JP) | 2024-09-11 | — | — | EP | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230000840-A1 | THERAPEUTIC AGENTS AND PROPHYLACTIC AGENTS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| EP-4059933-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2022-09-21 | — | — | EP | disclosed |
| EP-4059503-A1 | THERAPEUTIC AGENT AND PROPHYLACTIC AGENT FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | Nippon Shinyaku Co., Ltd. (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| CN-109689661-A | Macrocyclic inhibitors of myeloperoxidase | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | disclosed |
| US-20020128185-A1 | Pharmaceutical compounds | HAWAII, UNIVERSITY OF | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | TDP1 1172/4885HCRTR2 4552/4885EPHX1 2386/4885 |
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | PAM, CHRM3, AZI2 | TDP1 2111/4885HCRTR2 4493/4885EPHX1 3767/4885 |
| US-20020128185-A1 | Pharmaceutical compounds | XPO5, XPOT, XPO1 | TDP1 1266/4885HCRTR2 3588/4885EPHX1 4147/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | TDP1 1172/4885HCRTR2 4552/4885EPHX1 2386/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | TDP1 1172/4885HCRTR2 4552/4885EPHX1 2386/4885 |
| US-20230000840-A1 | THERAPEUTIC AGENTS AND PROPHYLACTIC AGENTS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | ALPI, SI, AZI2 | TDP1 899/4885HCRTR2 4567/4885EPHX1 3839/4885 |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | PAM, CHRM3, AZI2 | TDP1 1651/4885HCRTR2 4495/4885EPHX1 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.